Qpex Biopharma

Qpex Biopharma

  • Founded: 2018
  • Location: San Diego, CA
  • Employee range: 11 - 50
  • Clinical stage: Clin1b
  • Therapy area: Bacterial infections
  • Drug types: INF
  • Lead product: ORAvance (QPX7728)
  • Product link: https://www.qpexbio.com/pipeline
  • Funding: $33M Oct 2018


qpexbio.com

linkedin.com

job board


Short description:

Anti-infectives

Drug notes:

OMNIvance Clin1b bacterial infections; QPX9003 Clin1b bacterial infections; undisclosed programs RD undisclosed

Long description:

Qpex Biopharma is developing novel therapeutics to address the critical needs for the treatment of infectious diseases. Antimicrobial resistance (AMR) annually afflicts millions of patients worldwide and is a global health problem. However, treatment challenges in AMR often occur with specific pathogens and resistance mechanisms that impact far fewer people and are overlooked. By defining drug resistance mechanisms, Qpex is aiming to improve currently existing antibiotics rather than discovering new chemical classes of antibiotics. This way, Qpex can restore antibiotic potency against drug-resistant bacteria in a rational way that is more likely to be safe and effective. Qpex’s lead programs are both optimized variants of beta-lactamase inhibitors.

Jobs:


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com